StockData
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc (PRLD) stock

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3055% above fair value
$3.32−0.09 (-2.64%)

Close on Nov 17, 2026Market cap $264.95MP/E –Yield –

Prelude Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Prelude Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $22.42M, up 220.3% year over year. For fiscal 2025 it was $12.14M, up 73.4% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$12.14M+73.4%
FY2024Dec 31, 2024$7.00M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.70M–
Q1 FY2026Mar 31, 2026$4.58M–
Q4 FY2025Dec 31, 2025$5.64M+41.0%
Q3 FY2025Sep 30, 2025$6.50M+116.7%
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$0–
Q4 FY2024Dec 31, 2024$4.00M–
Q3 FY2024Sep 30, 2024$3.00M–

More Prelude Therapeutics figures

See a number that looks wrong?